Vaccinology update 2009: Questions around the safety of adjuvanted influenza A(H1N1) vaccines;Vaccinologie: Questions autour de la sécurité des vaccins adjuvantés contre la grippe A(H1N1)

Revue Medicale Suisse

Volumn 6, Issue 231, 2010, Pages 67-70

  Siegrist, Claire Anne ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; MERCURY; SQUALENE;

AUTOIMMUNE DISEASE; DRUG FORMULATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GUILLAIN BARRE SYNDROME; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MEDICAL INFORMATION; MORTALITY; NEUROTOXICITY; REVIEW; RISK ASSESSMENT;

HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 76149084537     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. * Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009;27:3331-4.
2. Mosca F, Tritto E, Muzzi A, Monaci et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA;105:10501-6.
3. Immunogenicity, safety and reactogenicity of GSK Biologicals' influenza GSK2340272A and Fluarix™ 2009-2010 vaccines when co-administered in elderly subjects aged 61 years and older. www.gsk-clinicalstudyregister.com/ result-detail.jsp?protocolId=113525&studyId=27869&compound= H1n1+Pandemic+Influenza+Vaccine
4. ** Schultze V, D'Agosto V, Wack A, et al. Safety of MF59 adjuvant. Vaccine 2008;26:3209-22.
5. Leroux-Roels I, Roman F, Forgus S, et al. Priming with AS03(A)-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study. Vaccine 2009;epub ahead of print.
6. Galli G, Hancock K, Hoschler K, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 2009;106:7962-7.
7. Ansaldi F, Canepa P, Parodi V, et al. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: The importance of cross-protection. Vaccine 2009;27:3345-8.
8. Vesikari T, Pellegrini M, Karvonen A, et al. Enhanced Immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009;28:563-71.
9. Asa PB, Cao Y, Garry RF. Antibodies to squalene in Gulf War syndrome. Exp Mol Pathol 2000;68:55-64.
10. Phillips CJ, Matyas GR, Hansen CJ, et al. Antibodies to squalene in US Navy persian gulf war veterans with chronic multisymptom illness. Vaccine 2009;27:3921-6.
11. Del Giudice G, Fragapane E, Bugarini R, et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol 2006;13:1010-3.
12. Spanggord RJ, Sun M, Lim P, Ellis WY. Enhancement of an analytical method for the determination of squalene in anthrax vaccine adsorbed formulations. J Pharm Biomed Anal 2006;42:494-9.
13. ** Black S, Eskola J, Siegrist CA, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009;epub ahead of print.
14. Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barré syndrome. Drug Saf 2009;32:309-23.
15. Juurlink DN, Stukel TA, Kwong J, et al. Guillain-Barre syndrome after influenza vaccination in adults: A population-based study. Arch Intern Med 2006;166:2217-21.
16. ** Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom general practice research database. Am J Epidemiol 2009;169:382-8.
17. ** Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database. Vaccine 2009;27:6959-65.
18. Rutschmann OT, McCrory DC, Matchar DB. Immunization panel of the multiple sclerosis council for clinical practice guidelines. Immunization and MS: A summary of published evidence and recommendations. Neurology 2002;59:1837-43.
19. Comité consultatif mondial de l'OMS sur la sécurité des vaccins. Thiomersal et vaccins. www.who.int/vaccine-safety/topics/ thiomersal/fr/index.html
20. European Medicine Agency (EMEA). Pandemic influenza (H1N1) website. www.emea.europa.eu/influenza/newsroom/newsroom.html